Cardio-focused company Kardigan is sewing a new digital data platform into its R&D patchwork through the acquisition of heart ...

"This unique platform has the potential to overcome historical ... Sanofi has signed a series of deals to expand its R&D capabilities, fuelled in part by its blockbuster immunology brand Dupixent ...

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically ...

Albert’s AI-enabled platform transforms materials science R&D and accelerates chemical innovation Albert Invent, whose end-to-end R&D platform accelerates chemical innovation in materials ...

The Company plans to showcase its R&D progress and platform innovation, including updates on multiple near- and mid-stage potentially transformative therapies that represent blockbuster ...

Bayer is paying $1.5 billion upfront to claim ownership of Vividion's drug discovery platform, which uses chemoproteomics ... Vividion's in-house R&D efforts are still at the preclinical stage ...

The insurance platform will be integrated into ... With its in-house research and development (R&D) capabilities, Leapmotor's ...

Syneron has granted AstraZeneca access to its Synova™ platform, a high-throughput macrocyclic peptide drug R&D platform designed to advance research “exploring possible future treatments of ...

“Our independent in-house R&D began in 2009 and since then we have established our small molecule drug platform and biopharmaceutical platform,” Hui says. “Over the last four years, in ...

OAKLAND, Calif.--(BUSINESS WIRE)--Albert Invent, whose end-to-end R&D platform accelerates chemical innovation in materials science through the application of AI and machine learning, today ...

as well as manufacturing innovations to improve efficiency – – Company will webcast its R&D Day event today at 9:00 a.m. E.T – “Alnylam is driving the field of RNAi therapeutics into the ...